Imatinib and Nilotinib inhibit Bcr-Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 183-189

  Landry, William D ^a   Woolley, John F ^a   Cotter, Thomas G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bcr Abl; Chronic Myelogenous Leukaemia; GSK 3 ; Imatinib; NADPH oxidase; Nilotinib; P22phox; Reactive oxygen species

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE SUBUNIT P22PHOX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UO 126;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRESS; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; K562 CELLS; NADPH OXIDASE; OXIDATION-REDUCTION; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84872418752     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.003     Document Type: Article

References (36)

1. Rowley J.D. New consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 1973, 243:290-293.
2. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 1985, 315:550-554.
3. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
4. Sattler M., Verma S., Shrikhande G., Byrne C.H., Pride Y.B., Winkler T., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000, 275:24273-24278.
5. Naughton R., Quiney C., Turner S.D., Cotter T.G. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009, 23:1432-1440.
6. Kim J.H., Chu S.C., Gramlich J.L., Pride Y.B., Babendreier E., Chauhan D., et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005, 105:1717-1723.
7. Nowicki M.O., Falinski R., Koptyra M., Slupianek A., Stoklosa T., Gloc E., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004, 104:3746-3753.
8. Rassool F.V., Gaymes T.J., Omidvar N., Brady N., Beurlet S., Pla M., et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?. Cancer Res 2007, 67:8762-8771.
9. Sallmyr A., Fan J., Rassool F.V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008, 270:1-9.
10. Bedard K., Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
11. Groeger G., Quiney C., Cotter T.G. Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 2009, 11:2655-2671.
12. Ambasta R.K., Kumar P., Griendling K.K., Schmidt H.H.H.W., Busse R., Brandes R.P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004, 279:45935-45941.
13. Ueno N., Takeya R., Miyano K., Kikuchi H., Sumimoto H., The NADPH Oxidase Nox3 constitutively produces superoxide in a p22phox-dependent manner. J Biol Chem 2005, 280:23328-23339.
14. 2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling. PLoS One 2012, 7:e34050.
15. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
16. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000, 15:17-28.
17. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1:493-502.
18. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
19. Luo J. Glycogen synthase kinase 3beta (GSKbeta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009, 273:194-200.
20. Choi C.-H., Lee B.-H., Ahn S.-G., Oh S.-H. Proteasome inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation of glycogen synthase kinase 3β. Biochem Biophys Res Commun 2012, 418:759-764.
21. Hole P.S., Darley R.L., Tonks A. Do reactive oxygen species play a role in myeloid leukemias?. Blood 2011, 117:5816-5826.
22. Sardina J.L., Lopez-Ruano G., Sanchez-Abarca L.I., Perez-Simon J.A., Gaztelumendi A., Trigueros C., et al. p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation. Cell Death Differ 2010, 17:1842-1854.
23. Reddy M.M., Fernandes M.S., Salgia R., Levine R.L., Griffin J.D., Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia 2011, 25:281-289.
24. Weyemi U., Lagente-Chevallier O., Boufraqech M., Prenois F., Courtin F., Caillou B., et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 2012, 31:1117-1129.
25. Weyemi U., Dupuy C. The emerging role of ROS-generating NADPH oxidase NOX4 in DNA-damage responses. Mutat Res 2012, 751:77-81.
26. Koptyra M., Falinski R., Nowicki M.O., Stoklosa T., Majsterek I., Nieborowska-Skorska M., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.
27. Lambeth J.D., Kawahara T., Diebold B. Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med 2007, 43:319-331.
28. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006, 290:661-673.
29. Petry A., Djordjevic T., Weitnauer M., Kietzmann T., Hess J., Gorlach A. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 2006, 8:1473-1484.
30. Peshavariya H., Dusting G., Jiang F., Halmos L., Sobey C., Drummond G., et al. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:193-204.
31. Block K., Gorin Y., Hoover P., Williams P., Chelmicki T., Clark R.A., et al. NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem 2007, 282:8019-8026.
32. Block K., Gorin Y., New D.D., Eid A., Chelmicki T., Reed A., et al. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol 2010, 176:2447-2455.
33. Cai H., Li Z., Davis M.E., Kanner W., Harrison D.G., Dudley S.C. Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol Pharmacol 2003, 63:325-331.
34. Yokoyama H., Ikehara Y., Kodera Y., Ikehara S., Yatabe Y., Mochizuki Y., et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006, 95:1504-1513.
35. Jeong H.Y., Jeong H.Y., Kim C.D. p22phox-derived superoxide mediates enhanced proliferative capacity of diabetic vascular smooth muscle cells. Diabetes Res Clin Pract 2004, 64:1-10.
36. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103:4010-4022.